SEDAR Interim Financial Statements

[
  {
    "companyName": "CONAVI MEDICAL CORP.",
    "reportingPeriodEnd": "2025-12-31",
    "reportStatus": "Unaudited",
    "auditorName": null,
    "auditorKeyMatters": [],
    "balanceSheet": {
      "cashAndCashEquivalents": 971,
      "restrictedCash": 959,
      "accountsReceivableAndOtherReceivables": 381,
      "inventory": 71,
      "prepaidExpensesSupplierDepositsAndOtherAssets": 3063,
      "investmentTaxCreditsRecoverable": 326,
      "totalCurrentAssets": 5771,
      "propertyAndEquipment": 1175,
      "intangibleAssets": 2211,
      "rightOfUseAssets": 682,
      "totalAssets": 9839,
      "accountsPayableAndAccruedLiabilities": 4947,
      "financingLiability": 959,
      "currentPortionOfDeferredRevenue": 519,
      "currentPortionOfLoansPayable": 1129,
      "leaseLiabilities": 598,
      "warrantLiability": 1423,
      "totalCurrentLiabilities": 9575,
      "deferredRevenue": 4131,
      "loansPayable": 16284,
      "leaseLiabilitiesNonCurrent": 603,
      "totalLiabilities": 30593,
      "commonShares": 126787,
      "preFundedWarrants": 6116,
      "contributedSurplus": 16466,
      "cumulativeTranslationAdjustment": -417,
      "deficit": -169706,
      "totalShareholdersDeficiency": -20754,
      "cashPerShare": 0.0000,
      "workingCapitalPerShare": -0.0495
    },
    "incomeStatement": {
      "licensingAndRDServicesRevenue": 218,
      "productRevenues": 0,
      "totalRevenues": 218,
      "costOfSales": 0,
      "grossProfit": 218,
      "researchAndDevelopment": 2387,
      "generalAndAdministrative": 2433,
      "depreciationAndAmortization": 186,
      "otherExpenses": 356,
      "totalOperatingExpenses": 5362,
      "operatingLoss": 5144,
      "netFinanceCosts": -1068,
      "changeInFairValueOfWarrantLiability": -1371,
      "listingExpense": 0,
      "netLoss": 2705,
      "foreignCurrencyTranslationAdjustment": 254,
      "comprehensiveLoss": 2959,
      "basicAndDilutedLossPerCommonShare": 0.04,
      "weightedAverageSharesOutstanding": 76750086
    },
    "cashFlowStatement": {
      "netLoss": -2705,
      "depreciationOfPropertyAndEquipment": 63,
      "amortizationOfIntangibleAssets": 59,
      "depreciationOfRightOfUseAssets": 64,
      "interestAccruedAndAccretionExpense": 329,
      "stockBasedCompensation": 234,
      "impairmentOfPropertyAndEquipment": 0,
      "netLossOnDisposalOfPropertyAndEquipment": 0,
      "unrealizedForeignExchangeGain": -1216,
      "changeInFairValueOfWarrantLiability": -1371,
      "listingExpense": 0,
      "deferredRevenue": -88,
      "otherIncome": -21,
      "nonCashLicensingAndRDServicesRevenue": -218,
      "changesInWorkingCapitalInventories": 270,
      "changesInWorkingCapitalAccountsReceivableAndOtherReceivables": 26,
      "changesInWorkingCapitalInvestmentTaxCreditsRecoverable": -60,
      "changesInWorkingCapitalAccountsPayableAndAccruedLiabilities": 2043,
      "changesInWorkingCapitalPrepaidExpensesAndSupplierDeposits": -1649,
      "netCashUsedInOperatingActivities": -4240,
      "purchaseOfPropertyAndEquipment": -30,
      "purchaseOfIntangibleAssets": -115,
      "proceedsFromTheTransaction": 0,
      "netCashUsedInInvestingActivities": -145,
      "paymentOfLeaseLiabilities": -266,
      "paymentOfLoansPayableAndInterest": -219,
      "proceedsFromPrivatePlacement": 0,
      "netCashFlowsUsedInFinancingActivities": -485,
      "increaseDecreaseInCashAndCashEquivalents": -4870,
      "cashAndCashEquivalentsBeginningOfPeriod": 5841,
      "cashAndCashEquivalentsEndOfPeriod": 971
    },
    "investmentsAndOtherAssets": [],
    "shareStructure": {
      "authorizedShares": "unlimited",
      "issuedShares": 76750086,
      "classesOfShares": ["common shares", "pre-funded warrants"],
      "warrants": [
        {
          "number": 7152841,
          "exercisePrice": 1.35,
          "expiryDate": "2029-10-11"
        },
        {
          "number": 933280,
          "exercisePrice": 1.35,
          "expiryDate": "2029-10-11"
        },
        {
          "number": 8140592,
          "exercisePrice": 1.35,
          "expiryDate": "2029-10-11"
        },
        {
          "number": 32693,
          "exercisePrice": 1.08,
          "expiryDate": "2026-10-11"
        },
        {
          "number": 2521050,
          "exercisePrice": 0.4,
          "expiryDate": "2027-04-23"
        },
        {
          "number": 17500000,
          "exercisePrice": 0.00001,
          "expiryDate": null
        },
        {
          "number": 124935,
          "exercisePrice": 50,
          "expiryDate": "2026-01-26"
        }
      ],
      "options": [
        {
          "number": 6786958,
          "exercisePrice": 0.87,
          "expiryDate": null
        }
      ],
      "rightsConvertibleInstruments": null
    },
    "managementCompensation": {
      "currency": "CAD",
      "periods": {
        "threeMonthsEndedDecember312025": {
          "salariesAndEmployeeBenefits": 416,
          "terminationBenefits": 281,
          "directorsFees": 149,
          "shareBasedCompensation": 161,
          "total": 1007
        },
        "threeMonthsEndedDecember312024": {
          "salariesAndEmployeeBenefits": 217,
          "terminationBenefits": 0,
          "directorsFees": 98,
          "shareBasedCompensation": 51,
          "total": 366
        }
      },
      "namedIndividuals": [],
      "otherRelatedPartyTransactions": []
    },
    "subsequentEvents": [
      {
        "eventDate": "2026-01-13",
        "description": "Closed an equity offering for aggregate gross proceeds of $12,000. Issued 26,666,670 common shares.",
        "impactValue": 12000
      },
      {
        "eventDate": "2026-02-25",
        "description": "Entered a share for debt settlement arrangement with MaRs Investment Accelerator Fund Inc. Settled the debt by issuing 75,000 common shares for the outstanding balance of $270 at December 31, 2025.",
        "impactValue": 270
      }
    ]
  }
]